After the first report of FGFR3-TACC3 fusion in glioblastoma, these fusions were reported in numerous solid cancers, including urothelial carcinoma, non-small-cell lung cancer, thyroid cancer, and uterine cervical carcinoma. This evidence concerns the gene TACC3 and urothelial carcinoma.